Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

• Rhona Johnston,
• Olalekan Uthman,
• Ewen Cummins,
• Christine Clar,
• Pamela Royle,
• Jill Colquitt,
• Bee Kang Tan,
• Andrew Clegg,
• Saran Shantikumar,
• Rachel Court,
• J Paul O’Hare,
• David McGrane,
• Tim Holt,
• Norman Waugh

Affiliations

Rhona Johnston

McMDC, Harrogate, UK

Olalekan Uthman

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK

Ewen Cummins

McMDC, Harrogate, UK

Christine Clar

Berlin, Germany

Pamela Royle

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK

Jill Colquitt

Effective Evidence, Waterlooville, UK

Bee Kang Tan

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK

Andrew Clegg

University of Central Lancashire, Preston, UK

Saran Shantikumar

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK

Rachel Court

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK

J Paul O’Hare

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK

David McGrane

Queen Elizabeth University Hospital, Glasgow, UK

Tim Holt

University of Oxford, Oxford, UK

Norman Waugh

Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK